Citations

Showing 10 of 108083 citations.

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
Hegen, Harald , Walde, Janette , Berek, Klaus , Arrambide, Georgina , Gnanapavan, Sharmilee , Kaplan, Batia , Khalil, Michael , Saadeh, Ruba , Teunissen, Charlotte E. , Teunissen, Charlotte E , Deisenhammer, Florian , Tumani, Hayrettin , Villar, Luisa María , Willrich, Maria Alice V. , Zetterberg, Henrik

Mayo Clinic

Multiple Sclerosis Journal | December 1, 2022 | Volume: 29 | Issue: 2 | Pages: 169-181

10.1177/13524585221134213 | PMID 36453167 Get It

Background: Intrathecal immunoglobulin-G synthesis is a hallmark of multiple sclerosis (MS), which can be detected by oligoclonal IgG bands (OCB) or by κ-free light chains (κ-FLC) in cerebrospinal fluid. Objective: To perform a systematic review and meta-analysis to evaluate whether κ-FLC index has similar diagnostic value to identify patients with clinically isolated syndrome (CIS) or MS compared to OCB, and to determine κ-FLC index cut-off. Methods: PubMed was searched for studies that assessed diagnostic sensitivity and specificity of κ-FLC index and OCB to discriminate CIS/MS patients from control subjects. Two reviewers following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines performed study eligibility assessment and data extraction. Findings from studies were analyzed with bivariate mixed models. Results: A total of 32 studies were included in the meta-analysis to evaluate diagnostic value of κ-FLC index. Sensitivity and specificity ranged from 52% to 100% (weighted average: 88%) and 69% to 100% (89%) for κ-FLC index and from 37% to 100% (85%) and 74% to 100% (92%) for OCB. Mean difference of sensitivity and specificity between κ-FLC index and OCB was 2 and −4 percentage points. Diagnostic accuracy determined by mixed models revealed no significant difference between κ-FLC index and OCB. A discriminatory cut-off for κ-FLC index was determined at 6.1. Conclusion: The findings indicate that κ-FLC index has similar diagnostic accuracy in MS as OCB.
Surgical approaches for proximal interphalangeal joint arthroplasty
Renfree, Kevin J. , Renfree, Kevin

Mayo Clinic

The Bone & Joint Journal | December 1, 2022 | Volume: 104-B | Issue: 12 | Pages: 1329-1333

10.1302/0301-620x.104b12.bjj-2022-0946 | PMID 36453047 Get It

This annotation reviews current concepts on the three most common surgical approaches used for proximal interphalangeal joint arthroplasty: dorsal, volar, and lateral. Advantages and disadvantages of each are highlighted, and the outcomes are discussed. Cite this article: Bone Joint J 2022;104-B(12):1329–1333.
Concerns surrounding application of artificial intelligence in hip and knee arthroplasty
Jain, Samagra, Pang, Michael , Karnuta, Jaret M. , Nawabi, Danyal H. , Polisetty, Teja S. , Vigdorchik, Jonathan M. , Wyles, Cody C. , Ramkumar, Prem N.

Mayo Clinic

The Bone & Joint Journal | December 1, 2022 | Volume: 104-B | Issue: 12 | Pages: 1292-1303

10.1302/0301-620x.104b12.bjj-2022-0922.r1 | PMID 36453039 Get It

Literature surrounding artificial intelligence (AI)-related applications for hip and knee arthroplasty has proliferated. However, meaningful advances that fundamentally transform the practice and delivery of joint arthroplasty are yet to be realized, despite the broad range of applications as we continue to search for meaningful and appropriate use of AI. AI literature in hip and knee arthroplasty between 2018 and 2021 regarding image-based analyses, value-based care, remote patient monitoring, and augmented reality was reviewed. Concerns surrounding meaningful use and appropriate methodological approaches of AI in joint arthroplasty research are summarized. Of the 233 AI-related orthopaedics articles published, 178 (76%) constituted original research, while the rest consisted of editorials or reviews. A total of 52% of original AI-related research concerns hip and knee arthroplasty (n = 92), and a narrative review is described. Three studies were externally validated. Pitfalls surrounding present-day research include conflating vernacular (“AI/machine learning”), repackaging limited registry data, prematurely releasing internally validated prediction models, appraising model architecture instead of inputted data, withholding code, and evaluating studies using antiquated regression-based guidelines. While AI has been applied to a variety of hip and knee arthroplasty applications with limited clinical impact, the future remains promising if the question is meaningful, the methodology is rigorous and transparent, the data are rich, and the model is externally validated. Simple checkpoints for meaningful AI adoption include ensuring applications focus on: administrative support over clinical evaluation and management; necessity of the advanced model; and the novelty of the question being answered. Cite this article: Bone Joint J 2022;104-B(12):1292–1303.
The management of sacral tumours
Rose, Peter S.

Mayo Clinic

The Bone & Joint Journal | December 1, 2022 | Volume: 104-B | Issue: 12 | Pages: 1284-1291

10.1302/0301-620x.104b12.bjj-2022-0734.r1 | PMID 36453038 Get It

Tumours of the sacrum are difficult to manage. The sacrum provides the structural connection between the torso and lower half of the body and is subject to both axial and rotational forces. Thus, tumours or their treatment can compromise the stability of the spinopelvic junction. Additionally, nerves responsible for lower limb motor groups as well as bowel, bladder, and sexual function traverse or abut the sacrum. Preservation or sacrifice of these nerves in the treatment of sacral tumours has profound implications on the function and quality of life of the patient. This annotation will discuss current treatment protocols for sacral tumours. Cite this article: Bone Joint J 2022;104-B(12):1284–1291.
Facial Nerve Schwannoma Treatment with Stereotactic Radiosurgery (SRS) versus Resection followed by SRS: Outcomes and a Management Protocol
Dayawansa, Sam , Mantziaris, Georgios , Mehta, Gautam U. , Leković, Gregory P. , Mathieu, David , Reda, Wael A. , Lee, Cheng-chia, Barnet, Gene, Lunsford, L. Dade , Sheehan, Jason P. , Mehta, Gautam U , Mathieu, David , Trifiletti, Daniel M , Mantziaris, Georgios , Dumot, Chloé , Kondziolka, Douglas , Reda, Wael A. , Liščák, Roman , Kaufmann, Anthony M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 1, 2022 | Volume: 85 | Issue: 01 | Pages: 075-080

10.1055/a-1990-2861 | PMID 38274481 Get It

Abstract Background Stereotactic radiosurgery (SRS) and resection are treatment options for patients with facial nerve schwannomas without mass effect. Objective This article evaluates outcomes of patients treated with SRS versus resection + SRS. Method We retrospectively compared 43 patients treated with SRS to 12 patients treated with resection + SRS. The primary study outcome was unfavorable combined endpoint, defined as worsening or new clinical symptoms, and/or tumor radiological progression. SRS (38.81 ± 5.3) and resection + SRS (67.14 ± 11.8) groups had similar clinical follow-ups. Results At the time of SRS, the tumor volumes of SRS (mean ± standard error; 1.83 ± 0.35 mL) and resection + SRS (2.51 ± 0.75 mL) groups were similar. SRS (12.15 ± 0.08 Gy) and resection + SRS (12.16 ± 0.14 Gy) groups received similar radiation doses. SRS group (42/43, 98%) had better local tumor control than the resection + SRS group (10/12, 83%, p = 0.04). Most of SRS (32/43, 74%) and resection + SRS (10/12, 83%) group patients reached a favorable combined endpoint following SRS (p = 0.52). Considering surgical associated side effects, only 2/10 patients of the resection + SRS group reached a favorable endpoint (p < 0.001).Patients of SRS group, who are > 34 years old (p = 0.02), have larger tumors (> 4 mL, 0.04), internal auditory canal (IAC) segment tumor involvement (p = 0.01) were more likely to reach an unfavorable endpoint. Resection + SRS group patients did not show such a difference. Conclusion While resection is still needed for larger tumors, SRS offers better clinical and radiological outcomes compared to resection followed by SRS for facial schwannomas. Younger age, smaller tumors, and non-IAC situated tumors are factors that portend a favorable outcome.
Thyroidal Angiotensin-Converting Enzyme 2 Protein Expression and Thyroid Function Tests in Patients with COVID-19: Results from a Retrospective Case Series and a Prospective Cohort Study
Koehler, Viktoria Florentine , Hasmann, Sandra E. , Scherer, Clemens , Muenchhoff, Maximilian , Munker, Stefan , Hoster, Eva , Ladurner, Roland , Spitzweg, Christine , Hoster, Eva , Scherer, Clemens , Knösel, Thomas , Hellmuth, Johannes C.

Mayo Clinic

Thyroid® | December 1, 2022 | Volume: 33 | Issue: 2 | Pages: 177-185

10.1089/thy.2022.0229 | PMID 36453232 Get It

Background: Infection with SARS-CoV-2 has initially been known as a respiratory disease but in the course of the pandemic the understanding has emerged that severity is owing to fatal inflammatory responses apart from lung injury. In this context, endocrine disorders such as thyroiditis as well as pituitary dysfunction in addition to nonthyroidal illness syndrome have been described. Furthermore, angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 cell receptor, has been detected in most endocrine tissues, including the thyroid gland. Objective: To evaluate histopathologic changes and compare thyroidal ACE2 protein expression in thyroid tissue from patients who died from severe COVID-19 with thyroid tissue from patients without SARS-CoV-2 infection in a retrospective case series. Furthermore, to assess and compare alterations in thyroid function tests (TFTs) between patients with or without SARS-CoV-2 infection as well as association of TFTs with the severity of the disease in a prospective cohort study. Methods: Thyroid tissue of deceased COVID-19 patients ( n = 23) was analyzed for histopathology and ACE2 expression by immunohistochemical staining. A total of 153 patients with confirmed SARS-CoV-2 were evaluated regarding TFTs and divided into a severe (intubation, intensive care treatment) and an intermediate group. Results: Thyroidal ACE2 expression was detected in 87% of the deceased COVID-19 patients. Normal thyroid tissue from patients without SARS-CoV-2 infection showed no ACE2 protein expression. Half of the severely ill COVID-19 patients had low free triiodothyronine (fT3) levels. Combination of low fT3 and thyrotropin (TSH) was associated significantly with deadly disease. Conclusion: The high percentage of positive ACE2 immunostaining in deceased patients compared with normal thyroid tissue of patients without SARS-CoV-2 infection suggests involvement of the thyroid in COVID-19, although further research will have to show the pathogenic role of thyroidal ACE2 in COVID-19. Abnormal fT3 and a TSH of ≤0.5 mU/L were associated with a fatal outcome in our severely ill SARS-CoV-2 patient cohort. Therefore, assessment of TFTs is crucial in the treatment of severely ill COVID-19 patients. Trial Registration: COVID-19 Registry of the LMU University Hospital Munich (CORKUM), WHO trial ID DRKS00021225.
ASHP Foundation Pharmacy Forecast 2023: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
Nesbit, Todd, Reuland, Charles, Cunningham, Francesca , Schweitzer, Pamela, Chisholm‐Burns, Marie A., Martinez, Leyner, Shane, Rita , Scott, Christopher M., Nelson, Scott D. , Mize, Dara, Devender, Elva Angelique Van, Oyen, Lance J., Nelson, Scott D. , Oyen, Lance, DiPiro, Joseph T. , Chisholm‐Burns, Marie A. , Nelson, Scott D

Mayo Clinic

American Journal of Health-System Pharmacy | December 1, 2022 | Volume: 80 | Issue: 2 | Pages: 10-35

10.1093/ajhp/zxac274 | PMID 36450306 Get It

Effects of age and time since injury on traumatic brain injury blood biomarkers: a TRACK-TBI study
Puccio, Ava M. , Korley, Frederick K. , Okonkwo, David O. , Puffer, Ross C. , Yuh, Esther L. , Yue, John K. , Sun, Xiaoying, Taylor, Sabrina R. , Mukherjee, Pratik , Jain, Sonia , Manley, Geoffrey T. , Investigators, the TRACK-TBI, Feeser, V. Ramana, Ferguson, Adam R. , Gaudette, Etienne, Gopinath, Shankar P. , McCrea, Michael , Merchant, Randall E., Robertson, Claudia S. , Vassar, Mary J. , Zafonte, Ross , Mukherjee, Pratik , Gardner, Raquel C. , Wang, Kevin , Diaz‐Arrastia, Ramon , Investigators, the TRACK-TBI, Gaudette, Etienne, Keene, C. Dirk , Madden, Christopher, Martin, Alastair J. , Ngwenya, Laura Benjamin , Temkin, Nancy R.

Mayo Clinic

Brain Communications | November 30, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac316 | PMID 36642999 Get It

Abstract Older adults have the highest incidence of traumatic brain injury globally. Accurate blood-based biomarkers are needed to assist with diagnosis of patients across the spectrum of age and time post-injury. Several reports have suggested lower accuracy for blood-based biomarkers in older adults, and there is a paucity of data beyond day-1 post-injury. Our aims were to investigate age-related differences in diagnostic accuracy and 2-week evolution of four leading candidate blood-based traumatic brain injury biomarkers—plasma glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, S100 calcium binding protein B and neuron-specific enolase—among participants in the 18-site prospective cohort study Transforming Research And Clinical Knowledge in Traumatic Brain Injury. Day-1 biomarker data were available for 2602 participants including 2151 patients with traumatic brain injury, 242 orthopedic trauma controls and 209 healthy controls. Participants were stratified into 3 age categories (young: 17–39 years, middle-aged: 40–64 years, older: 65–90 years). We investigated age-stratified biomarker levels and biomarker discriminative abilities across three diagnostic groups: head CT-positive/negative; traumatic brain injury/orthopedic controls; and traumatic brain injury/healthy controls. The difference in day-1 glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1 and neuron-specific enolase levels across most diagnostic groups was significantly smaller for older versus younger adults, resulting in a narrower range within which a traumatic brain injury diagnosis may be discriminated in older adults. Despite this, day-1 glial fibrillary acidic protein had good to excellent performance across all age-categories for discriminating all three diagnostic groups (area under the curve 0.84–0.96; lower limit of 95% confidence intervals all &gt;0.78). Day-1 S100 calcium-binding protein B and ubiquitin carboxy-terminal hydrolase L1 showed good discrimination of CT-positive versus negative only among adults under age 40 years within 6 hours of injury. Longitudinal blood-based biomarker data were available for 522 hospitalized patients with traumatic brain injury and 24 hospitalized orthopaedic controls. Glial fibrillary acidic protein levels maintained good to excellent discrimination across diagnostic groups until day 3 post-injury irrespective of age, until day 5 post-injury among middle-aged or younger patients and until week 2 post-injury among young patients only. In conclusion, the blood-based glial fibrillary acidic protein assay tested here has good to excellent performance across all age-categories for discriminating key traumatic brain injury diagnostic groups to at least 3 days post-injury in this trauma centre cohort. The addition of a blood-based diagnostic to the evaluation of traumatic brain injury, including geriatric traumatic brain injury, has potential to streamline diagnosis.
Hiding in Plain Sight
Naser, Jwan A. , Fogwe, Delvise T. , Ho, Matthew , Shah, Aditya , Fogwe, Delvise, Corsini Campioli, Cristina , Naser, Jwan A , Ho, Matthew , Campioli, Cristina Corsini

Mayo Clinic

New England Journal of Medicine | November 30, 2022 | Volume: 387 | Issue: 22 | Pages: 2075-2081

10.1056/nejmcps2205021 | PMID 36449424 Get It

Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis
Li, Yawei , Xin, Wu , Yang, Ping , Jiang, Guoqian , Luo, Yuan , Yang, Ping , Luo, Yuan

Mayo Clinic

Genomics, Proteomics & Bioinformatics | November 30, 2022 | Volume: 20 | Issue: 5 | Pages: 850-866

10.1016/j.gpb.2022.11.003 | PMID 36462630 Get It

Abstract The recent development of imaging and sequencing technologies enables systematic advances in the clinical study of lung cancer. Meanwhile, the human mind is limited in effectively handling and fully utilizing the accumulation of such enormous amounts of data. Machine learning-based approaches play a critical role in integrating and analyzing these large and complex datasets, which have extensively characterized lung cancer through the use of different perspectives from these accrued data. In this review, we provide an overview of machine learning-based approaches that strengthen the varying aspects of lung cancer diagnosis and therapy, including early detection, auxiliary diagnosis, prognosis prediction, and immunotherapy practice. Moreover, we highlight the challenges and opportunities for future applications of machine learning in lung cancer.